LifeTech Reports Steady Growth of 32.5percent in Net Profit Attributable to Owners of the Company in 2022

SHENZHEN, China, March 29, 2023 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "Lifetech"), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced its 2022 annual results. During the year ended 31 December 2022, Lifetech achieved a revenue of approximately RMB1,097.3 million, increased by 18.6% year on year. The...

Related Keywords

China ,Shenzhen ,Guangdong ,United States ,Japan ,Bankura ,Ankara ,Turkey , ,Aortic Branch Stent Graft System ,Aortic Arch Branch Stent Graft System ,Adult Congenital Heart Disease Center ,Lifetech Scientific Corporation ,Ministry Of Food ,Lifetech Scientific Corporation Stock Code ,National Medical Products Administration ,Drug Administration For Compassionate ,Showa University Hospital ,Lifetech Scientific Corporation The Company Or ,Left Atrial Appendage ,Congenital Heart Diseases ,Vena Cava Filter System ,Balloon Dilatation Catheter ,Stent Graft System ,Absorbable Atrial Septal Defect Closure System ,Sizing Balloon ,Arch Stent Graft System ,Plus Aortic Arch Stent Graft System ,Chimney Aortic Stent Graft System ,Pro Aortic Stent Graft System ,Endovascular Needle System ,Thoracoabdominal Artery Stent Graft System ,Iron Bioresorbable Scaffold System ,Drug Administration ,Prospective Multicenter Single Arm Target Study ,Concave Supra Arch ,Ventricular Septal Defect Occluder ,Pediatric Heart Disease ,Stock Code ,